Updates in Medicine | 🔬 REDEFINE 2: CagriSema in T2D + Obesity Original article link in bio 👥 Phase 3a RCT in 1206 adults with T2D (BMI ≥27, HbA1c 7–10%) 💉 US$ 24.45 Min. order: 1 piece ★★★★★ 4.6 (215 reviews) Sold : Login>>
Novo Nordisk's latest trial results for its next-generation obesity drug CagriSema disappointed investors by failing to show superior outcomes to existing drugs. ➡️ CagriSema, which includes a nascent form of weight loss US$ 27.53 Min. order: 1 piece ★★★★★ 4.9 (133 reviews) Sold : Login>>
Targeting the weight within: obesity pharmacotherapy in cardiovascular disease US$ 21.65 Min. order: 1 piece ★★★★★ 4.0 (278 reviews) Sold : Login>>
Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants - Gabe - 2024 - Diabetes, Obesity and Metabolism US$ 21.97 Min. order: 1 piece ★★★★★ 4.6 (80 reviews) Sold : Login>>